Literature DB >> 9343288

Tyrosinemia type III: diagnosis and ten-year follow-up.

R Cerone1, E Holme, M C Schiaffino, U Caruso, L Maritano, C Romano.   

Abstract

Tyrosinemia type III, caused by deficiency of 4-hydroxyphenylpyruvate dioxygenase, is a rare disorder of tyrosine catabolism. Primary 4-hydroxyphenylpyruvate dioxygenase deficiency has been described in only three patients. The biochemical phenotype shows hypertyrosinemia and elevated urinary excretion of 4-hydroxyphenyl derivatives. We report the clinical and biochemical findings and the results of long-term follow-up in a new patient with this disorder presenting with severe mental retardation and neurological abnormalities. The clinical phenotype is compared with those reported in the three previously described patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343288     DOI: 10.1111/j.1651-2227.1997.tb15192.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  11 in total

1.  Outcome of tyrosinaemia type III.

Authors:  C J Ellaway; E Holme; S Standing; M A Preece; A Green; E Ploechl; M Ugarte; F K Trefz; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

2.  Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia.

Authors:  C J Wilson; K G Van Wyk; J V Leonard; P T Clayton
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

3.  Novel Cranial Imaging Findings and a Splice-Site Variant in a Patient with Tyrosinemia Type III, and a Summary of Published Cases.

Authors:  Ayca Burcu Kahraman; Halil Tuna Akar; Naz Güleray Lafcı; Yılmaz Yıldız; Ayşegül Tokatlı
Journal:  Mol Syndromol       Date:  2022-01-04

4.  Activation of homology-directed DNA repair plays key role in CRISPR-mediated genome correction.

Authors:  Gourish Mondal; Caitlin J VanLith; Clara T Nicolas; Whitney S Thompson; William S Cao; Lori Hillin; Benjamin J Haugo; Daniel R O' Brien; Jean-Pierre Kocher; Robert A Kaiser; Joseph B Lillegard
Journal:  Gene Ther       Date:  2022-10-19       Impact factor: 4.184

5.  Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

Authors:  P Gissen; M A Preece; H A Willshaw; P J McKiernan
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

6.  NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.

Authors:  A Masurel-Paulet; J Poggi-Bach; M-O Rolland; O Bernard; N Guffon; D Dobbelaere; J Sarles; H Ogier de Baulny; G Touati
Journal:  J Inherit Metab Dis       Date:  2008-01-25       Impact factor: 4.982

7.  Tyrosinemia type III in an asymptomatic girl.

Authors:  Edyta Szymanska; Malgorzata Sredzinska; Elzbieta Ciara; Dorota Piekutowska-Abramczuk; Rafal Ploski; Dariusz Rokicki; Anna Tylki-Szymanska
Journal:  Mol Genet Metab Rep       Date:  2015-10-22

Review 8.  TYROSINEMIA TYPE III: A CASE REPORT OF SIBLINGS AND LITERATURE REVIEW.

Authors:  Fábio Barroso; Joana Correia; Anabela Bandeira; Carla Carmona; Laura Vilarinho; Manuela Almeida; Júlio César Rocha; Esmeralda Martins
Journal:  Rev Paul Pediatr       Date:  2020-06-05

Review 9.  A Proposed Diagnostic Algorithm for Inborn Errors of Metabolism Presenting With Movements Disorders.

Authors:  Juan Darío Ortigoza-Escobar
Journal:  Front Neurol       Date:  2020-11-13       Impact factor: 4.003

10.  A Case of Tyrosinemia Type III with Status Epilepticus and Mental Retardation.

Authors:  Reza Najafi; Neda Mostofizadeh; Mahin Hashemipour
Journal:  Adv Biomed Res       Date:  2018-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.